FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL 3235-0287 Estimated average burden

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Ferayorni Justin John						2. Issuer Name and Ticker or Trading Symbol STREAMLINE HEALTH SOLUTIONS INC. [STRM]								heck all app	,		10%	Owner	
(Last) 2400 OL	(Last) (First) (Middle) 2400 OLD MILTON PARKWAY					3. Date of Earliest Transaction (Month/Day/Year) 07/18/2024								belov		ille	belo	er (specify w)	
BOX 1353					4. If Amendment, Date of Original Filed (Month/Day/Year)									5. Individual or Joint/Group Filing (Check Applicable ine) Form filed by One Reporting Person					
(Street) ALPHARETTA GA 30009													Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State) (Zip)					Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Table	I - N	Non-Deriva	ative S	Secu	rities	Ac	quire	ed, Di	sposed of	, or E	Benefici	ally Own	ed				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Y				ear) E	2A. Deemed Execution Date, if any (Month/Day/Year		9,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a 5)			5. Amount Securities Beneficial Owned Fo	Form: (D) or I (I) (Inst		Direct ndirect r. 4)	7. Nature of ndirect Beneficial Dwnership		
									Code	v .	Amount	(A) or (D)	Price	Reported Transaction (Instr. 3 ar	ction(s)			Instr. 4)	
Common Stock, \$0.01 par value 07/18/2024					24	1			A ⁽¹⁾		250,000(1)	A	\$0.5	833,633(2)		D			
Common Stock, \$0.01 par value														4,930,882		I		Refer to Cootnote ⁽³⁾⁽⁴⁾	
		Tai	ble l	II - Derivati (e.g., ρι						,	posed of, convertib			•	d				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Exe if ar	cution Date,		Transaction Code (Instr.		rative rities pired r psed) r. 3, 4	Exp	ate Exei iration I nth/Day		7. Title and Amount of Securities Underlying Derivative Security (Instr 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Num derivat Securit Benefic Owned Followi Report Transa (Instr. 4	ive dies dially ing ed ction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ct (Instr. 4)	
					Code	v	(A)	(D)	Date Exe	e rcisable	Expiration Date	Title	Amount or Number of Shares						

Explanation of Responses:

- 1. Grant of shares of restricted stock that vest in full on the earlier of (i) July 18, 2025 and (ii) the date of, and immediately prior to, the issuer's 2025 annual meeting of stockholders, subject to the reporting person's continuous service through such vesting date
- 2. The reported securities represent shares owned directly by Mr. Ferayorni.
- 3. The reported securities represent 4,244,334 shares held directly by Tamarack Global Healthcare Fund, L.P. ("Fund 1") and 686,548 shares held directly by Tamarack Global Healthcare Fund QP, L.P. ("Fund 2"). Tamarack Capital Management, LLC is the general partner of Fund 1 and Fund 2, Tamarack Advisors, LP is the investment advisor to Fund 1 and Fund 2, and Justin J. Ferayorni is the sole managing member of both Tamarack Capital Management, LLC and Tamarack Capital GP, LLC. Tamarack Capital Management, LLC, Tamarack Advisors, LP, and Mr. Ferayorni may be deemed indirect beneficial owners of the shares held by Fund 1 and Fund 2 for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Act").
- 4. Tamarack Capital Management, LLC, Tamarack Advisors, LP, and Mr. Ferayorni disclaim beneficial ownership of any of the shares held by Fund 1 and Fund 2 for the purpose of determining whether they are subject to Section 16 of the Act, however, in reliance on Rule 16a-1(a)(v) and (vii) under the Act. To the extent that they might be deemed subject to Section 16, they disclaim beneficial ownership of securities held by the Fund 1 and Fund 2 for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein, if any.

/ Bryant J Reeves III, 07/19/2024 attorney-in-fact

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.